These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19471115)

  • 41. Systemic β-Adrenergic Receptor Activation Augments the
    Baker FL; Bigley AB; Agha NH; Pedlar CR; O'Connor DP; Bond RA; Bollard CM; Katsanis E; Simpson RJ
    Front Immunol; 2019; 10():3082. PubMed ID: 32038628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Porcine γδ T lymphocytes can be categorized into two functionally and developmentally distinct subsets according to expression of CD2 and level of TCR.
    Stepanova K; Sinkora M
    J Immunol; 2013 Mar; 190(5):2111-20. PubMed ID: 23359501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded Vγ2Vδ2 T Cells.
    Yang R; Shen S; Gong C; Wang X; Luo F; Luo F; Lei Y; Wang Z; Xu S; Ni Q; Xue Y; Fu Z; Zeng L; Fang L; Yan Y; Zhang J; Gan L; Yi J; Zhou P
    Front Immunol; 2021; 12():654080. PubMed ID: 34040604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immobilized MICA could expand human Vdelta1 gammadelta T cells in vitro that displayed major histocompatibility complex class I chain-related A-dependent cytotoxicity to human epithelial carcinomas.
    Qi J; Zhang J; Zhang S; Cui L; He W
    Scand J Immunol; 2003 Aug; 58(2):211-20. PubMed ID: 12869143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
    Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunophenotype and function define TCRγδ + T-ALL as a distinct subgroup from TCRαβ + T-ALL patients.
    Mirji G; Banavali S; Sengar M; Chiplunkar SV
    Leuk Lymphoma; 2020 Jan; 61(1):108-117. PubMed ID: 31393182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
    Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
    J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.
    Zhao H; Xi X; Cui L; He W
    Cell Mol Immunol; 2012 Mar; 9(2):147-54. PubMed ID: 21909128
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
    Caldwell SA; Ryan MH; McDuffie E; Abrams SI
    J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
    Poonia B; Pauza CD
    Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis.
    Chen S; Lv T; Sun G; Li S; Duan W; Zhang C; Jin H; Tian D; Li M; Shan S; Ma H; Ou X; You H; Zhang D; Jia J
    Hepatol Int; 2022 Feb; 16(1):195-206. PubMed ID: 35028922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
    Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
    Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
    Kabelitz D; Wesch D; Pitters E; Zöller M
    J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
    [TBL] [Abstract][Full Text] [Related]  

  • 56. γδ T-cell immunotherapy for lung cancer.
    Yoshida Y; Nakajima J; Wada H; Kakimi K
    Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
    Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
    Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.
    Knight A; Arnouk H; Britt W; Gillespie GY; Cloud GA; Harkins L; Su Y; Lowdell MW; Lamb LS
    PLoS One; 2013; 8(8):e68729. PubMed ID: 23950874
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation.
    Pereboeva L; Harkins L; Wong S; Lamb LS
    Cancer Immunol Immunother; 2015 May; 64(5):551-62. PubMed ID: 25676710
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
    Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
    J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.